Avelox Articles
New Zealand’s PHARMAC enters deal with InterPharma for seven cancer drugs and with Bayer over Xarelto, Avelox and Copaxone
10 November 2010
Venezuela invalidates two Bayer moxifloxacin patents
30 November 2009
Bayer hit by charges and falling material science sales in 1st qtr, but pharma division doing well
29 April 2009
Schering-Plough finally back in profit after Organon buy; exceeds expectations, pleasing shareholders
9 February 2009
EMEA proposes limiting use of Bayer's moxifloxacin
4 August 2008
Black box warnings on fluoroquinolone
14 July 2008
Strong data for Bayer's Avelox in CAP
26 May 2008
Stock Commentary - Europe - week to Oct 29, 2007
5 November 2007
Court rules for Bayer on Avelox patents
5 November 2007
S-P's 2nd-quarter 2007 EPS doubles to $0.34
30 July 2007
Bayer sues over Teva's US generic Avelox
16 April 2007
Shionogi's six-month income drops 23%
20 November 2006
UPDATE: ICAAC 2006 sees strong data on next-gen antibiotics: Tygacil, ceftaroline, cethromycin
9 October 2006
Strong efficacy data for S-P's Avelox
9 October 2006
Bayer's Avelox "as effective" as potent combo regimen for CA pneumonia
11 September 2006
Bayer welcomes strong data on Avelox in ABS
29 May 2006
Shionogi's 2005 sales 196.4B yen, down 1.5%
29 May 2006
Bayer AG sees record-breaking 1st qtr with EBIT up 8.2% to $1.56 billion on strong health care sales
8 May 2006
S-P announces positive Avelox study data
17 April 2006
S-Ps Avelox outperforms Levaquin in CAP study
6 February 2006
Japan stock market week to Dec 5
12 December 2005
FDA OKs S-P/Bayer's Avelox for 6th indication
12 December 2005
Bayer's Avelox approved for cSSSI in EU
15 August 2005
Bayer and Schering-Plough form strategic pharmaceuticals alliance
20 September 2004
Bayer sees shares dip on mixed 2nd-qtr
6 September 2004
Bayer's Avelox cleared by FDA for new use
24 May 2004
Bayer continues to focus on anti-infectives
10 May 2004
Dr Reddy's files ANDA for moxifloxacin tabs
5 April 2004
Bayer's Avelox superior in AECB
15 March 2004
Stock Commentary - Europe
16 February 2004
Bayer says Avelox patent valid until 2014
9 February 2004
Profits up at Bayer on acquisition benefits
12 May 2003
Avelox FDA-approved for new indication
10 March 2003
First Euro approval for Bayer's Avalox IV
13 May 2002
Bayer realigns US pharma sales force
11 February 2002
Bayer's Avelox IV cleared in USA
5 December 2001
Fast-track review for Isis
15 November 2000
Operating income up 31% at Bayer
10 August 2000
Stock Commentary Tokyo
29 June 2000
Daiichi's advantage in antibiotic class
20 June 2000
Bayer's Avelox versus Zithromax in ABECB
11 May 2000
Bayer's US health care sales jump 21% in 1999
31 March 2000
Bayer structure to remain intact UPDATE
20 March 2000
Bayer signs genomics deal with Incyte
12 January 2000
Busy year for NCEs as major new compound classes launched
6 January 2000
First approval for B-MS' Tequin heats up antibiotic sector - update
30 December 1999
First approval for B-MS' Tequin heats up antibiotic sector
24 December 1999
W-L withdraws clinafloxacin NDA
21 December 1999
SmithKline Beecham files for US approval of new quinolone
16 December 1999
Bayer's quinolone moxifloxacin approved in USA
16 December 1999
Bayer gets backing from FDA panel for moxifloxacin
25 October 1999
Johnson & Johnson wins FDA panel backing for Levaquin in CAP
21 October 1999
Bayer health care has failed to deliver growth, say GS analysts
24 September 1999
Showing 1-77 of 77 articles
- 1
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
